Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cannara BiotechLOVFF +2.03%88 Earnings per Share (Diluted) is $0.08 as of May. 2026. GuruFocus rates LOVFF with a GF Score™ of 88/100 and a GF Value™ of $1.22 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 785 Drug Manufacturers companies, Cannara Biotech ranks better than 95.41% on this metric.
Cannara Biotech's EPS (Basic) for the
three
months ended in May. 2026 was $0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in May. 2026 was $0.08.
During the past 12 months, Cannara Biotech's average EPS without NRIGrowth Rate was -36.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 76.30% per year.
During the past 8 years, Cannara Biotech's highest 3-Year average EPS without NRI Growth Rate was 76.30% per year. The lowest was -48.40% per year. And the median was 13.95% per year.
Cannara Biotech (OTCPK:LOVFF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Cannara Biotech Earnings per Share (Diluted) Related Terms
Cannara Biotech Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech Earnings per Share (Diluted) Chart
LOVFF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's PE Ratio falls into.
Cannara Biotech Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Cannara Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Aug. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.08 mean?
Cannara Biotech (LOVFF) has a Earnings per Share (Diluted) of $0.08 as of May. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #36 out of 785 companies in the Drug Manufacturers industry, placing it in the top 4.6%.
Is Cannara Biotech's Earnings per Share (Diluted) too high?
Cannara Biotech's current Earnings per Share (Diluted) is $0.08. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.70. Cannara Biotech's value of $0.08 is 99.2% below this industry median. Based on the distribution chart, Cannara Biotech ranks #36 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cannara Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #36 out of 785 companies for Earnings per Share (Diluted). This places Cannara Biotech in the top 5% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 9.70. Cannara Biotech's value of $0.08 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Earnings per Share (Diluted) of $0.08 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Earnings per Share (Diluted) is $0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.22, compared to a current price of $1.46 — trading 19.7% above its estimated fair value. The current Earnings per Share (Diluted) is $0.08 and 99.2% below the Drug Manufacturers industry median of 9.70. Cannara Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Earnings per Share (Diluted) is $0.08 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.46 is trading 19.7% above its estimated GF Value™ of $1.22.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
Earnings per Share (Diluted): $0.08
GF Value™: $1.22 vs. price of $1.46 (19.7% above fair value)
Industry Position: 99.2% below the Drug Manufacturers median (#36 of 785)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
88GF Score
Get the complete analysis for LOVFF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
